key: cord-0800364-41eu6oa4
authors: Jat, Kana Ram
title: COVID-19 in Children: What We Know and What We Don’t Know?
date: 2021-09-01
journal: Indian J Pediatr
DOI: 10.1007/s12098-021-03933-z
sha: e589c210200b1e94557dfd87a08c8d4cebd5814d
doc_id: 800364
cord_uid: 41eu6oa4

nan

The infectivity and duration of infectivity of children with COVID-19 are not well studied. Further, the infectivity of asymptomatic children with COVID-19 and the risk of disease spread is not known.

The vaccination for COVID-19 is found to be effective in adults. There are few concerns about the vaccine in children. The trials of the vaccine are from adults, though some trials are going on in children. Most of the cases in children are mild, and the safety of the vaccine, especially long-term safety, in children is unknown; therefore, the blanket vaccination of all children should be viewed with caution [5] . Further, about half of the children are already seropositive for COVID-19 antibodies in India. As most severe/critical cases and almost all deaths due to COVID-19 occur in children with underlying comorbidity, this group of children should be considered for vaccination. Further, we have to see the effects of vaccination on the multisystem inflammatory syndrome in children (MIS-C).

World Health Organisation. WHO Coronavirus Disease (COVID-19) Dashboard

Pediatric COVID Management Team. Clinical profile, hospital course and outcome of children with COVID-19

Clinical profile and risk factors for severe disease in 402 children hospitalized with SARS-CoV-2 from India: collaborative Indian pediatric COVID study group

Clinical features and outcome of SARS-CoV-2 infection in children: a systematic review and meta-analysis

Should we delay covid-19 vaccination in children?

Conflict of Interest None.